Compare Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion NASDAQ 100 Equal Weighted Index Shares vs Travere Therapeutics Inc. Common Stock — how do they compare? Direxion NASDAQ 100 Equal Weighted Index Shares trades at $117.79 (market cap $1.46B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 3.3× Direxion NASDAQ 100 Equal Weighted Index Shares's market cap, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion NASDAQ 100 Equal Weighted Index Shares for 50 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| QQQE | TVTX | |
|---|---|---|
Market Cap | $1.46B | $4.88B |
Volume | 175,669 | 1,668,577 |
Sector | Broad Market / Factor | Health |
52-Week High | $124.69 | $67.52 |
52-Week Low | $96.06 | $26.79 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQE (Direxion NASDAQ-100 Equal Weighted Index ETF) trades at $120.45, down 0.4% on the day with a bearish technical signal from moving averages. The ETF provides equal-weighted exposure to NASDAQ-100 companies, reducing technology concentration from 60% to 45% compared to market-cap weighted alternatives. Recent analysis suggests QQQE offers stronger fundamentals and technicals than QQQ for tactical positioning over the next twelve months.
The equal-weight approach provides diversification benefits amid tech sector volatility, though the bearish technical trend and neutral oscillators suggest near-term consolidation. Key risks include NASDAQ concentration and market volatility, while the strategy appeals to investors seeking reduced tech exposure within large-cap growth stocks.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
